These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33022649)

  • 21. The implications of baseline bone-health assessment at initiation of androgen-deprivation therapy for prostate cancer.
    Kirk PS; Borza T; Shahinian VB; Caram MEV; Makarov DV; Shelton JB; Leppert JT; Blake RM; Davis JA; Hollenbeck BK; Sales A; Skolarus TA
    BJU Int; 2018 Apr; 121(4):558-564. PubMed ID: 29124881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Androgen-deprivation Therapy on Bone Mineral Density in Japanese Patients with Prostate Cancer.
    Miyazawa Y; Sekine Y; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
    In Vivo; 2018; 32(2):409-412. PubMed ID: 29475929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving bone health in men with prostate cancer receiving androgen deprivation therapy: Results of a randomized phase 2 trial.
    Alibhai SMH; Breunis H; Timilshina N; Hamidi MS; Cheung AM; Tomlinson GA; Manokumar T; Samadi O; Sandoval J; Durbano S; Warde P; Jones JM
    Cancer; 2018 Mar; 124(6):1132-1140. PubMed ID: 29211305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
    Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy.
    Suarez-Almazor ME; Peddi P; Luo R; Nguyen HT; Elting LS
    Support Care Cancer; 2014 Feb; 22(2):537-44. PubMed ID: 24146343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy.
    Bruder JM; Ma JZ; Basler JW; Welch MD
    Urology; 2006 Jan; 67(1):152-5. PubMed ID: 16413352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
    Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD
    Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines.
    Cheung AS; Pattison D; Bretherton I; Hoermann R; Lim Joon D; Ho E; Jenkins T; Hamilton EJ; Bate K; Chan I; Zajac JD; Grossmann M
    Andrology; 2013 Jul; 1(4):583-9. PubMed ID: 23686896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term effects of androgen deprivation therapy in prostate cancer patients.
    Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy.
    Dalla Via J; Daly RM; Owen PJ; Mundell NL; Rantalainen T; Fraser SF
    Bone; 2019 Oct; 127():367-375. PubMed ID: 31189088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
    Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
    Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer.
    Morote J; Morin JP; Orsola A; Abascal JM; Salvador C; Trilla E; Raventos CX; Cecchini L; Encabo G; Reventos J
    Urology; 2007 Mar; 69(3):500-4. PubMed ID: 17382153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of bone mass density on patients with prostate cancer prior to the start of androgen deprivation therapy.
    Ziaran S; Goncalves FM; Wendl J; Trebaticky B; Breza JS
    Bratisl Lek Listy; 2009; 110(9):559-62. PubMed ID: 19827339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of Biomechanical Computed Tomography for Fracture Risk Classification in Metastatic Hormone-sensitive Prostate Cancer.
    Lin JK; Hearn CM; Getzen E; Long Q; Lee DC; Keaveny TM; Jayadevappa R; Robinson KW; Wong YN; Maxwell KN; Narayan V; Haas NB; Takvorian SU; Bikle DD; Chiang JM; Khan AN; Rajapakse CS; Morgans AK; Parikh RB
    Eur Urol Oncol; 2024 Aug; 7(4):794-803. PubMed ID: 37926618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone health and its correlates in Korean prostate cancer patients receiving androgen deprivation therapy.
    Kim SH; Seong do H; Yoon SM; Choi YD; Song Y; Song H; Choi E
    Eur J Oncol Nurs; 2016 Apr; 21():197-204. PubMed ID: 26522218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of osteoporosis in men on androgen deprivation therapy.
    Adler RA
    Maturitas; 2011 Feb; 68(2):143-7. PubMed ID: 21129866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of androgen deprivation therapy on serum levels of sclerostin, Dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis.
    Wang A; Karunasinghe N; Plank LD; Zhu S; Osborne S; Brown C; Bishop K; Schwass T; Tijono S; Holmes M; Masters J; Huang R; Keven C; Ferguson LR; Lawrenson R
    Sci Rep; 2021 Jul; 11(1):14905. PubMed ID: 34290287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence and risk factors for low trauma fractures in men with prostate cancer.
    Ahlborg HG; Nguyen ND; Center JR; Eisman JA; Nguyen TV
    Bone; 2008 Sep; 43(3):556-60. PubMed ID: 18585119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of six months of aerobic and resistance training on metabolic markers and bone mineral density in older men on androgen deprivation therapy for prostate cancer.
    Papadopoulos E; Mina DS; Culos-Reed N; Durbano S; Ritvo P; Sabiston CM; Krahn M; Tomlinson G; O'Neill M; Iqbal A; Timilshina N; Matthew A; Warde P; Alibhai SMH
    J Geriatr Oncol; 2020 Sep; 11(7):1074-1077. PubMed ID: 32143995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.